vs
Apellis Pharmaceuticals, Inc.（APLS）与Brilliant Earth Group, Inc.（BRLT）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Brilliant Earth Group, Inc.的1.6倍（$199.9M vs $124.4M），Brilliant Earth Group, Inc.净利率更高（-2.3% vs -29.5%，领先27.2%），Brilliant Earth Group, Inc.同比增速更快（4.1% vs -5.9%），Brilliant Earth Group, Inc.自由现金流更多（$5.7M vs $-14.3M），过去两年Brilliant Earth Group, Inc.的营收复合增速更高（13.1% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Brilliant Earth是2005年8月由贝丝·格斯坦与埃里克·格罗斯伯格创立的美国珠宝企业，总部位于加利福尼亚州旧金山，主打标注为合规溯源的钻石与其他宝石珠宝，该品牌推动了 ethical 珠宝市场的发展，2017年曾有媒体对其部分产地来源声明提出质疑。
APLS vs BRLT — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $124.4M |
| 净利润 | $-59.0M | $-2.9M |
| 毛利率 | — | 55.9% |
| 营业利润率 | -25.6% | -0.0% |
| 净利率 | -29.5% | -2.3% |
| 营收同比 | -5.9% | 4.1% |
| 净利润同比 | -62.2% | -908.9% |
| 每股收益（稀释后） | $-0.40 | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $124.4M | ||
| Q3 25 | $458.6M | $110.3M | ||
| Q2 25 | $178.5M | $108.9M | ||
| Q1 25 | $166.8M | $93.9M | ||
| Q4 24 | $212.5M | $119.5M | ||
| Q3 24 | $196.8M | $99.9M | ||
| Q2 24 | $199.7M | $105.4M | ||
| Q1 24 | $172.3M | $97.3M |
| Q4 25 | $-59.0M | $-2.9M | ||
| Q3 25 | $215.7M | $-107.0K | ||
| Q2 25 | $-42.2M | $-166.0K | ||
| Q1 25 | $-92.2M | $-466.0K | ||
| Q4 24 | $-36.4M | $358.0K | ||
| Q3 24 | $-57.4M | $-141.0K | ||
| Q2 24 | $-37.7M | $185.0K | ||
| Q1 24 | $-66.4M | $139.0K |
| Q4 25 | — | 55.9% | ||
| Q3 25 | — | 57.6% | ||
| Q2 25 | — | 58.3% | ||
| Q1 25 | — | 58.6% | ||
| Q4 24 | — | 59.6% | ||
| Q3 24 | — | 60.8% | ||
| Q2 24 | — | 60.8% | ||
| Q1 24 | — | 59.9% |
| Q4 25 | -25.6% | -0.0% | ||
| Q3 25 | 48.7% | -0.6% | ||
| Q2 25 | -18.6% | -1.1% | ||
| Q1 25 | -50.0% | -3.8% | ||
| Q4 24 | -12.3% | 2.0% | ||
| Q3 24 | -24.0% | -1.1% | ||
| Q2 24 | -14.7% | 1.1% | ||
| Q1 24 | -36.0% | 0.9% |
| Q4 25 | -29.5% | -2.3% | ||
| Q3 25 | 47.0% | -0.1% | ||
| Q2 25 | -23.6% | -0.2% | ||
| Q1 25 | -55.3% | -0.5% | ||
| Q4 24 | -17.1% | 0.3% | ||
| Q3 24 | -29.2% | -0.1% | ||
| Q2 24 | -18.9% | 0.2% | ||
| Q1 24 | -38.5% | 0.1% |
| Q4 25 | $-0.40 | $-0.20 | ||
| Q3 25 | $1.67 | $-0.01 | ||
| Q2 25 | $-0.33 | $-0.01 | ||
| Q1 25 | $-0.74 | $-0.03 | ||
| Q4 24 | $-0.30 | $0.02 | ||
| Q3 24 | $-0.46 | $-0.01 | ||
| Q2 24 | $-0.30 | $0.01 | ||
| Q1 24 | $-0.54 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $79.1M |
| 总债务越低越好 | — | $0 |
| 股东权益账面价值 | $370.1M | $12.3M |
| 总资产 | $1.1B | $200.9M |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $79.1M | ||
| Q3 25 | $479.2M | $73.4M | ||
| Q2 25 | $370.0M | $133.6M | ||
| Q1 25 | $358.4M | $147.3M | ||
| Q4 24 | $411.3M | $161.9M | ||
| Q3 24 | $396.9M | $152.7M | ||
| Q2 24 | $360.1M | $152.2M | ||
| Q1 24 | $325.9M | $147.5M |
| Q4 25 | — | $0 | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $34.5M | ||
| Q1 25 | — | $54.5M | ||
| Q4 24 | — | $55.7M | ||
| Q3 24 | — | $58.1M | ||
| Q2 24 | — | $58.0M | ||
| Q1 24 | $93.1M | $58.8M |
| Q4 25 | $370.1M | $12.3M | ||
| Q3 25 | $401.2M | $12.0M | ||
| Q2 25 | $156.3M | $15.3M | ||
| Q1 25 | $164.2M | $14.9M | ||
| Q4 24 | $228.5M | $15.3M | ||
| Q3 24 | $237.1M | $14.5M | ||
| Q2 24 | $264.3M | $14.1M | ||
| Q1 24 | $266.7M | $13.3M |
| Q4 25 | $1.1B | $200.9M | ||
| Q3 25 | $1.1B | $203.0M | ||
| Q2 25 | $821.4M | $260.9M | ||
| Q1 25 | $807.3M | $269.6M | ||
| Q4 24 | $885.1M | $281.2M | ||
| Q3 24 | $901.9M | $273.2M | ||
| Q2 24 | $904.5M | $272.5M | ||
| Q1 24 | $831.9M | $268.2M |
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 2.26× | ||
| Q1 25 | — | 3.65× | ||
| Q4 24 | — | 3.63× | ||
| Q3 24 | — | 4.01× | ||
| Q2 24 | — | 4.13× | ||
| Q1 24 | 0.35× | 4.43× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $7.2M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $5.7M |
| 自由现金流率自由现金流/营收 | -7.1% | 4.6% |
| 资本支出强度资本支出/营收 | 0.1% | 1.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $5.8M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $7.2M | ||
| Q3 25 | $108.5M | $608.0K | ||
| Q2 25 | $4.4M | $9.1M | ||
| Q1 25 | $-53.4M | $-7.1M | ||
| Q4 24 | $19.4M | $14.1M | ||
| Q3 24 | $34.1M | $2.0M | ||
| Q2 24 | $-8.3M | $7.3M | ||
| Q1 24 | $-133.0M | $-5.8M |
| Q4 25 | $-14.3M | $5.7M | ||
| Q3 25 | $108.3M | $-3.0K | ||
| Q2 25 | $4.4M | $7.9M | ||
| Q1 25 | $-53.4M | $-7.9M | ||
| Q4 24 | $19.3M | $11.9M | ||
| Q3 24 | — | $674.0K | ||
| Q2 24 | $-8.4M | $6.5M | ||
| Q1 24 | $-133.3M | $-6.4M |
| Q4 25 | -7.1% | 4.6% | ||
| Q3 25 | 23.6% | -0.0% | ||
| Q2 25 | 2.5% | 7.3% | ||
| Q1 25 | -32.0% | -8.4% | ||
| Q4 24 | 9.1% | 10.0% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | -4.2% | 6.1% | ||
| Q1 24 | -77.3% | -6.5% |
| Q4 25 | 0.1% | 1.2% | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | 0.0% | 1.1% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | 0.0% | 1.8% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.0% | 0.8% | ||
| Q1 24 | 0.2% | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 39.36× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 39.51× | ||
| Q1 24 | — | -41.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
BRLT
| US | $120.3M | 97% |
| Non Us | $4.2M | 3% |
